Objectives-Previous randomised studies of mammography screening have shown a significant effect on breast cancer mortality, particularly in women aged 50-69 at randomisation. Breast cancer mortality has traditionally been studied by judgments on causes of death, either from cause of death registers or from medical records. In this study an alternative method was used, estimating the excess mortality associated with breast cancer. Setting-In 1990 two counties of northern Sweden started population based mammography screening ofwomen aged 40-74. The unscreened population in the two other counties of the same region were selected as controls. Results-Excess mortality associated with breast cancer was lower in the screened population, and was discernible three to four years after the start of screening. The relative risk estimate, based on the cumulative excess number of deaths from breast cancer during 1990-95 in the screened versus the control population aged 40-74 (at diagnosis of breast cancer), was 0.72 (95% confidence interval (CI) 0.53 to 0.99). For women aged 50-69 it was 0.67 (95% CI 0.46 to 0.99). In the 50-69 age group the estimated excess number of deaths from breast cancer during 1995 was 17.0 per 100000 women (95% CI 5.0 to 29.0) in the screened counties and 51.1 per 100 000 (95% CI 30.2 to 71.9) in the unscreened counties. Conclusions-Population based routine screening has substantial effects on breast cancer mortality in women aged 50-69. Estimation of excess mortality can be used in future studies to evaluate the effects of mammography screening on breast cancer mortality.
It has been shown in a number of randomised studies that screening with mammography decreases the mortality from breast cancer, at least in the age group 50-69 years. [1] [2] [3] [4] [5] [6] [7] Attempts have also been made to document the effects on breast cancer mortality of so-called service screening performed routinely on a whole population." In this study we analysed the geographical variation of mortality associated with breast cancer in relation to population based service screening with mammography in the northern region of Sweden.
Previous studies of the effects of mammography screening on mortality have been based on mortality data from recordings of causes of death. Such data often, to some degree, rely on subjective judgments of causes of death, which has been a reason for criticism"- 16 Therefore, a method based on a more objective technique would be an interesting alternative. In this study a methodology based on the estimation of excess mortality was used." 16 The method depends on incidence data from a cancer register and mortality data from official population registers but does not rely on causes of death data. This technique provides an objective evaluation of the mortality associated with a specific cancer, which is shown in this study on breast cancer.
Material and methods
The northern region of Sweden consists of four counties with a total population of about 900 000 inhabitants. The oncologic centre in the city of Umea administers the regional cancer register, which comprises data on cancer incidence in the northern region since 1958. The oncologic centre also holds population and mortality registers of the region. The cancer and population registers are continuously updated.
Incidence data for breast cancer were obtained from the cancer register for the years 1980-95. The prevalence of breast cancer was based on the accumulated incidence from 1990 to 1995, excluding subjects who died during the follow up period. Mortality data for the cohort prevalent with breast cancer and for the total population were extracted from the registers. Cases of breast cancer diagnosed after death-that is, at necropsy, were excluded. SCREENING Population based screening with mammography for early detection of breast cancer was Prevalence/IOO 000 Incidencel l 00 000 and started in 1990 in the counties of Norrbotten and Vasternorrland for all women aged 40-74. On 31 December 1994 the number of women aged 40-74 in Norrbotten was 54331 and in Vasternorrland 55 147. The corresponding numbers for the other two counties of the region, Vasterbotten and jamtland, were 50 982 and 27 447, respectively. In the county of Vasterbotten, population based screening was started in 1995, and the county council of Jiimtland is planning to start screening during 1996. These two counties were used as the control counties in this study. The interval between screening rounds was, on average, 20 months in Norrbotten and Vasternorrland, Thus in both these counties the fourth round of screening is now (1996) in progress. For the two screening counties together the attendance rates were 89%, 84%, and 84% for the first, second, and third screening rounds, respectively; the recall rates were 2.1 %, 1.8% and 2.2%, for these rounds.
EXCESS MORTAUTY RATE
The term "excess mortality" has been used in various contexts, but in this study the excess mortality rate was defined as the death rate in the general population due to the excess risk imposed by a specific disease," in this case, breast cancer.
The excess mortality rate, A, was estimated by
where a = the observed number of deaths within a cohort of subjects prevalent with cancer. a was assumed to be Poisson distributed with parameter AN + E E = the expected number of deaths in the prevalent cancer cohort, based on the general, or "background", mortality in the corresponding general population; E was considered as a known constant N = the number of subjects in the corresponding general population.
All incident cases of invasive breast cancer from 1990 to 1995 were collected from the regional cancer register, and stratified into age groups 40-49, 50-69, and 70-74 years, according to age at diagnosis. From these incident cases cohorts prevalent with breast cancer were created in the screened and control populations, respectively, comprising cases of breast cancer diagnosed during 1990-95. In these cohorts the observed number of deaths, 0, was obtained for each consecutive year during 1990-95. The corresponding expected number of deaths, E, was easily derived from the general ("background") mortality, extracted from the population register, and the prevalence of breast cancer diagnosed during 1990-95, determined as described above. The expression (0 -E) represents the excess number of deaths from breast cancer among the prevalent cases diagnosed during 1990-95. For the corresponding general population,(O -E)/N depicts an estimate of the excess mortality rate as defined above.
which has been used to compute confidence intervals.
Results
For women aged 40-74 there was no obvious difference in age adjusted breast cancer incidence between screened and control counties before the start of screening (table 1) . During the first screening round an incidence peak was seen. The prevalence of subjects with breast cancer diagnosed during 1990-95 was higher in the screened counties than in the control counties in women aged 40-74 (table 1) .
The estimated annual excess mortality rate from breast cancer during the studied years 1990-95 did not differ between screened and control counties for women of ages 40-49 ( fig  1A) and 70-74 (not shown) at diagnosis. For women aged 50-69 a lower mortality rate was found in the screened population from 1993 to 1995. For the last studied year (1995) the difference was clearly significant with 95% confidence intervals separated ( fig 1B) . Excess mortality analysed across all ages (40-74 years) differed between screened and control groups (not shown). Table 2 shows the observed numbers of deaths within the cohorts of women prevalent with breast cancer diagnosed during 1990-95 and aged 50-69 at diagnosis. The annual excess number of deaths within these cohorts of women, expressed per 100 000 person-years of the corresponding population, varied for the years 1990-95 as tabulated. For the calendar year 1995, the estimated excess number of breast cancer deaths per 100 000 person-years was 51.1 in the control counties and 17.0 in the screened counties, representing a difference between the two populations of 34 excess deaths per 100 000 women, attributable to breast cancer.
Relative risk estimates based on the cumulative excess number of deaths from breast cancer during 1990-95 in the screened and Table 2 Annual numbers of observed deaths among subjects aged 50-69 at diagnosis, prevalent with breast cancer diagnosed during 1990-95, and annual breast cancer excess mortality in the screened (S) and control (C) populations during the period 1990-95
Lenner, Jonsson 1995, six years after the start of screening, the excess mortality rate attributable to breast cancer was three times greater in the control population than in the screened population, for corresponding age groups-a statistically significant result. A difference in the excess mortality between the screened and unscreened populations could already be seen in 1993, three to four years after the start of screening.
In the age group 40-49 no significant difference was seen. There was a relatively small number of deaths in this group, however, and thus differences due to sources other than random variation were impossible to detect. The same was also true for the oldest age group (70-74 years). Across all ages (40-74 years) the screened and control populations also differed significantly-for example, the cumulative excess mortality from breast cancer during 1990-95 was greater in the control group, with a point estimate for relative risk of 0.72, which is comparable with observations in previous randomised studies. '-7 This study relates to routine screening, and thus differs from many earlier investigations which were prospective randomised studies.'·7 However, the differing excess mortality between the screened and unscreened populations was obvious for women aged 50-69 at diagnosis. The magnitude of the difference was at least as large as in the randomised trials, thus confirming the efficacy of mammography screening in a routine setting.
In this study breast cancer cases from the whole studied population were included from 1 January 1990. However, the mammography screening was progressively started during 1990 and 1991, to include the whole population of the investigated age groups when the first screening round was completed after 20 months. Thus an unknown number of nonscreened cases of breast cancer, diagnosed in the beginning of the study, were included in the screening group. If anything, this bias may have led to an overestimation of the mortality from breast cancer in the screened population and, consequently, an underestimation of the difference in breast cancer mortality between the screened and control populations.
In previous randomised trials ofmammography screening, age stratification was according to age at randomisation-that is, at the start of screening. These birth cohorts were followed up for deaths and causes of death throughout the study period, irrespective of the age when the breast cancer was diagnosed. Consequently, some women belonging to a younger age group at randomisation-for example, 40-49 years, might have been diagnosed and died from breast cancer after the age of 49. Thus the results for the younger group might have been biased. The longer the follow up time, the larger becomes this bias.
In this study, age strata were defined according to age at diagnosis, which excludes this kind of bias. However, instead, a lead time bias might have been introduced, if women who died from breast cancer during the study received their diagnosis at an earlier stage of the disease in the screened population than in c 1995 1994 1994 UJ the control counties. In this way women in ages around an age class borderline-for example, 50 years, might have been classified as belonging to the younger age group (40-49 years) if diagnosed before 50 in the screened population, whereas corresponding women in the control population might have been in the older group (50-69 years) at diagnosis, even though they had an otherwise comparable cancer and died from it at the same time. However, there were no prerequisites for this kind of bias in this study because the survival time of patients with breast cancer who died during the study was the same in the screened and unscreened populations. In fact, the mean survival time among prevalent breast cancer cases aged 50-69 at diagnosis who died in the screened population was 2.02 years (95% CI 1.72 to 2.33), which was shorter than the corresponding mean survival time of 2.25 years (95% CI 1.95 to 2.55) in the control population. This observation clearly justifies the use of age at diagnosis as a criterion for age in this study.
In the randomised studies of mammography screening the birth cohorts were defined according to age at randomisation and then followed up over time. In this study we also included all the new birth cohorts aged 40 who were invited to screening for each new year of the follow up time through 1995. This allowed us to include considerably more women in the study.
In this investigation an unconventional methodology for estimating mortality was used rather than the traditional technique, which is based on individual or aggregated data on causes of death. If aggregated data on causes of death for breast cancer mortality after 1990 had been used many unscreened cases with a diagnosis of breast cancer before 1990 would have been included in the screened population, leading to serious dilution of the results. Individual data on causes of death for patients in whom breast cancer was diagnosed after 1990 might have been obtained from the registers, but such data were only available up to 1993. Deaths occurring after 1993 would have required manual recording of causes of death from death certificates and medical records, which would have been very tedious.
In addition, determination of the true cause of death is often subjective or difficult, and sometimes impossible; this may result in overestimation, as well as underestimation, of the true breast cancer specific mortality. Excess mortality, on the other hand, estimates all mortality associated with breast cancer, even indirectly caused deaths, such as treatment induced mortality, or deaths caused by the 9 stress imposed by the cancer-for example, cardiovascular deaths or suicide. This methodology should, therefore, be more objective than procedures based on causes of death, thus giving a more valid estimation of the true impact on the mortality due to breast cancer.
In conclusion, this investigation has shown that an unconventional method, estimation of the excess mortality rate, can be used to determine the impact of mammography screening on mortality from breast cancer. The results are in ageement with earlier randomised studies,I-7 confirming that routine population based screening significantly lowers the mortality associated with breast cancer in women aged 50-69 at diagnosis. This effect is evident in the sixth year after the start of screening. A larger study is necessary to show any effect in women younger than 50.
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